News
-
-
-
-
-
-
PRESS RELEASE
Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program
Bausch Health and Salix Pharmaceuticals announce XIFAXAN selected for drug price negotiation program with CMS for 2027. Details on XIFAXAN and safety information included -
-
-
-
PRESS RELEASE
Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day
Bausch Health Companies Inc., Salix Pharmaceuticals, and healthcare organizations join forces for the second annual Opioid-Induced Constipation Awareness Day to raise awareness and support patients affected by OIC